Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hodgkin Disease: early-phase trial registry
3 of 21 indexed Hodgkin Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 3 currently recruiting · #797 of 28,707 conditions by registered trial count
Hodgkin Disease: 21 US clinical trials tracked, 3 recruiting.
Hodgkin Disease is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 3 of these trials.
Enrollment posture brief
Registry condition hodgkin-disease
OPEN 3 | RECR 14% | LATE 1 | EARLY 14 | RANK #797 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Hodgkin Disease lists 3 open slots (14% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hodgkin Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hodgkin Disease is recruiting below its size-band peers.
3 of 21 indexed trials (14.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hodgkin Disease trials is spread across many organizations.
Washington University School of Medicine accounts for 3 of 21 trials (14.3%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Hodgkin Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 64 among the 21 trials that report a genuine target (sentinel values excluded). 13 of those (61.9%) plan for fewer than 100 participants.
-
Hodgkin Disease research is mostly interventional.
18 interventional and 3 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Tissue Collection for Studies of Lymph Cancer
National Cancer Institute (NCI)
NCT01676805
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
National Cancer Institute (NCI)
NCT02682667
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT03739502
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
National Cancer Institute (NCI)
NCT00039676
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04459416
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
NCT02979522
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT06254495
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Baylor College of Medicine
NCT02287311
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Baylor College of Medicine
NCT01333046
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT02663297
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
Wake Forest University Health Sciences
NCT03935282
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Stanford University
NCT00388349
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Merck Sharp & Dohme
NCT03598608
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen
NCT01716806
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
NCT00241358
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Baylor College of Medicine
NCT00062868
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Washington University School of Medicine
NCT00733824
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT03755414
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Massachusetts General Hospital
NCT01758042
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics
NCT01149668
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hodgkin Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hodgkin Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hodgkin Disease page
21 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Hodgkin Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Hodgkin Disease trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hodgkin Disease condition card totals 21 registered trials; most-linked intervention AMD3100; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.